Early safety trial of ION269 for Alzheimer's in down syndrome ends after just one participant
NCT ID NCT06673069
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a drug called ION269 in adults with Down syndrome who also showed signs of Alzheimer's disease. The goal was to check if the drug was safe and tolerable when injected into the spinal fluid. Only one person took part, and the study was stopped early, so we have very little information about how well it works or what the risks might be.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ION269 (given as an injection into the spinal fluid)
What this could lead to
If successful, this could point toward a treatment to slow Alzheimer's disease in people with Down syndrome.
What could go wrong
This was a very early, tiny Phase 1 safety study with only 1 participant, and it was terminated early. It is far too small to know if the drug works or is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ionis Investigative Site
Indianapolis, Indiana, 46202, United States
-
Ionis Investigative Site
Kansas City, Kansas, 66205, United States
-
Ionis Investigative Site
Lexington, Kentucky, 40536, United States
-
Ionis Investigative Site
St Louis, Missouri, 63110, United States
-
Ionis Investigative Site
Madison, Wisconsin, 53705, United States
-
Ionis Investigative Site
Barcelona, 08041, Spain